ABHD3

Across TCGA pan-cancer cohorts, ABHD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABHD3 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ABHD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ABHD3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where ABHD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.519	0.867	<.001	68	view →
HNSC	DFS	Quartile	III,IV	1.000	0.266	.024	24	view →
CCRCC	DFS	Median	III,IV	0.105	0.904	.008	16	view →
UCEC	DFS	Tertile	All	0.778	1.000	.011	8	view →
LSCC	OS	Quartile	All	0.959	0.778	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABHD3–LUAD (OS)

Open the LUAD breakdown →